In this protocol, the investigators propose to evaluate the biochemical effects of imatinib
on sickle red blood cells (RBCs). Patients will be administered imatinib mesylate orally
following the guidelines previously established for use of imatinib in other disorders. The
biochemical effects of imatinib on sickle RBCs will be examined, including changes in their
levels of band 3 tyrosine phosphorylation and the abundances of RBC-derived microparticles in
their blood. In addition, the patients will be monitored for symptoms of sickle cell disease
(SCD). The investigators expect band 3 tyrosine phosphorylation to decrease dramatically in
patients treated with imatinib. The investigators also anticipate a reduction in the numbers
of RBC-derived microparticles in circulation (quantitated by assaying the number of
glycophorin A positive microparticles in peripheral blood samples by flow cytometry. Most
importantly, the investigators expect to see a reduction in the frequency of vaso-occlusive
crises, and possibly acute chest syndrome and utilization of opioids. The study duration is
planned as 6 months in order to provide adequate time for potential change in the primary
endpoints (e.g. percent irreversibly sickled cells).
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.